Newsfeeds Archive - Page 5 of 6

2 minute read

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic Data For DFD-29

December 20, 9:35 AM

Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of

DERM

1 minute read

Urica Therapeutics Expands Exclusive License Agreement With Fuji Yakuhin Co. Ltd. To Develop Dotinurad In Additional Territories Including Turkey, Middle East And North Africa

By Bill Haddad

December 14, 9:01 AM

Urica Therapeutics, Inc. ("Urica" or the "Company") (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary company focused on the

FBIO

1 minute read

Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio

By Vandana Singh

November 8, 1:26 PM

Avenue Therapeutics Inc (NASDAQ:ATXI) acquired Baergic Bio Inc pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech Inc (NASDAQ:FBIO).…

ATXI

25 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

October 21, 1:26 PM

On Friday morning, 446 companies hit new 52-week lows.

ABG

1 minute read

Mustang Bio Announces First Patient Treated In Multicenter Phase 1/2 Clinical Trial Of MB-106

By Bill Haddad

October 6, 8:33 AM

Mustang Bio, Inc.

FBIO

5 minute read

News

Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions

By Benzinga Newsdesk

October 6, 8:05 AM

Fortress Biotech Inc. (NASDAQ:FBIO) is a biopharmaceutical company focused on developing a range of high-potential treatments on its own and through its growing portfolio of subsidiaries and partner companies. With

CKPT

2 minute read

Earnings

Fortress Biotech Earnings Perspective: Return On Capital Employed

By Benzinga Insights

September 8, 10:39 AM

Benzinga Pro data, Fortress Biotech (NASDAQ:FBIO) reported Q2 sales of $18.89 million. Earnings fell to a loss of $53.93 million, resulting in a 9.0% decrease from last quarter.

FBIO

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

August 12, 5:35 PM

ALNA

1 minute read

Earnings

Fortress Biotech: Q2 Earnings Insights

By Benzinga Insights

August 11, 7:27 PM

Fortress Biotech (NASDAQ:FBIO) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

FBIO

1 minute read

Fortress Biotech Q2 EPS $(0.10) Up From $(0.17) YoY

By Bill Haddad

August 11, 5:25 PM

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.10) per share. This is a 41.18 percent increase over losses of $(0.17) per share from the same period last year.

FBIO